These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 22993335)

  • 1. Update on PEG-interferon α-2b as adjuvant therapy in melanoma.
    Di Trolio R; Simeone E; Di Lorenzo G; Grimaldi AM; Romano A; Ayala F; Caracò C; Mozzillo N; Ascierto PA
    Anticancer Res; 2012 Sep; 32(9):3901-9. PubMed ID: 22993335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma.
    Eggermont AM; Suciu S; Testori A; Santinami M; Kruit WH; Marsden J; Punt CJ; Salès F; Dummer R; Robert C; Schadendorf D; Patel PM; de Schaetzen G; Spatz A; Keilholz U
    J Clin Oncol; 2012 Nov; 30(31):3810-8. PubMed ID: 23008300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study.
    Grob JJ; Jouary T; Dréno B; Asselineau J; Gutzmer R; Hauschild A; Leccia MT; Landthaler M; Garbe C; Sassolas B; Herbst RA; Guillot B; Chene G; Pehamberger H
    Eur J Cancer; 2013 Jan; 49(1):166-74. PubMed ID: 22975216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum concentrations of pegylated interferon alpha-2b in patients with resected stage III melanoma receiving adjuvant pegylated interferon alpha-2b in a randomized phase III trial (EORTC 18991).
    Eggermont AM; Bouwhuis MG; Kruit WH; Testori A; ten Hagen T; Yver A; Xu C
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):671-7. PubMed ID: 19621225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group.
    Bottomley A; Coens C; Suciu S; Santinami M; Kruit W; Testori A; Marsden J; Punt C; Salès F; Gore M; Mackie R; Kusic Z; Dummer R; Patel P; Schadendorf D; Spatz A; Keilholz U; Eggermont A
    J Clin Oncol; 2009 Jun; 27(18):2916-23. PubMed ID: 19433686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies--EORTC 18991.
    Bouwhuis MG; Suciu S; Testori A; Kruit WH; Salès F; Patel P; Punt CJ; Santinami M; Spatz A; Ten Hagen TL; Eggermont AM
    J Clin Oncol; 2010 May; 28(14):2460-6. PubMed ID: 20385998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial.
    Hansson J; Aamdal S; Bastholt L; Brandberg Y; Hernberg M; Nilsson B; Stierner U; von der Maase H;
    Lancet Oncol; 2011 Feb; 12(2):144-52. PubMed ID: 21256809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991.
    Eggermont AM; Suciu S; Testori A; Kruit WH; Marsden J; Punt CJ; Santinami M; Salès F; Schadendorf D; Patel P; Dummer R; Robert C; Keilholz U; Yver A; Spatz A
    Eur J Cancer; 2012 Jan; 48(2):218-25. PubMed ID: 22056637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of pegylated interferon-alpha-2b as an adjuvant therapy in Japanese patients with malignant melanoma.
    Yamazaki N; Uhara H; Wada H; Matsuda K; Yamamoto K; Shimamoto T; Kiyohara Y
    J Dermatol; 2016 Oct; 43(10):1146-1153. PubMed ID: 27087489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An update on pegylated IFN-α2b for the adjuvant treatment of melanoma.
    Agarwala SS
    Expert Rev Anticancer Ther; 2012 Nov; 12(11):1449-59. PubMed ID: 23249109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant therapy with pegylated interferon-alfa2b vs observation in stage II B/C patients with ulcerated primary: Results of the European Organisation for Research and Treatment of Cancer 18081 randomised trial.
    Eggermont AMM; Rutkowski P; Dutriaux C; Hofman-Wellenhof R; Dziewulski P; Marples M; Grange F; Lok C; Pennachioli E; Robert C; van Akkooi ACJ; Bastholt L; Minisini A; Marshall E; Salès F; Grob JJ; Bechter O; Schadendorf D; Marreaud S; Kicinski M; Suciu S; Testori AAE
    Eur J Cancer; 2020 Jul; 133():94-103. PubMed ID: 32470710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peginterferon alph-2b (Sylatron) for melanoma.
    Med Lett Drugs Ther; 2011 Sep; 53(1373):76. PubMed ID: 21921873
    [No Abstract]   [Full Text] [Related]  

  • 13. Analysis of surrogate gene expression markers in peripheral blood of melanoma patients to predict treatment outcome of adjuvant pegylated interferon alpha 2b (EORTC 18991 side study).
    Busse A; Rapion J; Fusi A; Suciu S; Nonnenmacher A; Santinami M; Kruit WH; Testori A; Punt CJ; Dalgleish AG; Spatz A; Eggermont AM; Keilholz U
    Cancer Immunol Immunother; 2013 Jul; 62(7):1223-33. PubMed ID: 23624802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant interferon therapy for malignant melanoma: the debate.
    Zhou Q; Zhang XS
    Chin J Cancer; 2010 Nov; 29(11):907-13. PubMed ID: 20979689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant treatment with pegylated interferon α-2a versus low-dose interferon α-2a in patients with high-risk melanoma: a randomized phase III DeCOG trial.
    Eigentler TK; Gutzmer R; Hauschild A; Heinzerling L; Schadendorf D; Nashan D; Hölzle E; Kiecker F; Becker J; Sunderkötter C; Moll I; Richtig E; Pönitzsch I; Pehamberger H; Kaufmann R; Pföhler C; Vogt T; Berking C; Praxmarer M; Garbe C;
    Ann Oncol; 2016 Aug; 27(8):1625-32. PubMed ID: 27287206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.
    Eggermont AM; Suciu S; MacKie R; Ruka W; Testori A; Kruit W; Punt CJ; Delauney M; Sales F; Groenewegen G; Ruiter DJ; Jagiello I; Stoitchkov K; Keilholz U; Lienard D;
    Lancet; 2005 Oct; 366(9492):1189-96. PubMed ID: 16198768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial.
    Eggermont AM; Suciu S; Santinami M; Testori A; Kruit WH; Marsden J; Punt CJ; Salès F; Gore M; MacKie R; Kusic Z; Dummer R; Hauschild A; Musat E; Spatz A; Keilholz U;
    Lancet; 2008 Jul; 372(9633):117-126. PubMed ID: 18620949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient preferences for adjuvant interferon alfa-2b treatment.
    Kilbridge KL; Weeks JC; Sober AJ; Haluska FG; Slingluff CL; Atkins MB; Sock DE; Kirkwood JM; Nease RF
    J Clin Oncol; 2001 Feb; 19(3):812-23. PubMed ID: 11157035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of pegylated interferon-alpha-2a in adjuvant therapy of intermediate and high-risk melanomas.
    Loquai C; Nashan D; Hensen P; Luger TA; Grabbe S; Sunderkötter C; Schiller M
    Eur J Dermatol; 2008; 18(1):29-35. PubMed ID: 18086586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sylatron: a pegylated interferon for use in melanoma.
    Patel JN; Walko CM
    Ann Pharmacother; 2012 Jun; 46(6):830-8. PubMed ID: 22619474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.